Amphastar Pharmaceuticals, Inc. AMPH
Updated: 17 Jun 2026
No signal published yet
We already track Amphastar Pharmaceuticals and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Amphastar Pharmaceuticals, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Amphastar Pharmaceuticals free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On May 7, 2026, the company reported Q1 2026 financial results that missed analyst estimates due to rising costs. In February 2026, Amphastar received FDA approval for Ipratropium Bromide HFA, a generic inhaler granted 180 days of market exclusivity. The company is currently transitioning its pipeline toward proprietary medicines and biosimilars to drive long-term growth.
What Firelda Watch includes for Amphastar Pharmaceuticals, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Amphastar Pharmaceuticals, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Amphastar Pharmaceuticals free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more